Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer-Reference-Cited by-同舟云学术

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer

Published:2010-01-23 Issue:1 Volume:28 Page:57-63
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Sari Ebru,Guler Gulnur,Hayran Mutlu,Gullu Ibrahim,Altundag Kadri,Ozisik Yavuz

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-010-9418-2.pdf

Reference34 articles.

1. Early breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

2. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.

3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

4. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer. 1995;14:227–51.

5. Teixeira MR, Pandis N, Bardi G, et al. Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer. 1995;63:63–8.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer;Journal of Cancer Research and Clinical Oncology;2024-03-11

2. Dynamic whole-body [18F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer;EJNMMI Research;2024-03-04

3. Fluorine-18-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies—AJR Expert Panel Narrative Review;American Journal of Roentgenology;2023-12-20

4. Study of Biomarker Discordance between Primary and Recurrent Sites and its Clinical Implications in Metastatic Breast Cancer : A Single Institutional Study from India;South Asian Journal of Cancer;2023-12-08

5. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2023-04-24